Viewing Study NCT05586061


Ignite Creation Date: 2025-12-24 @ 1:06 PM
Ignite Modification Date: 2025-12-30 @ 8:04 PM
Study NCT ID: NCT05586061
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-07
First Post: 2022-10-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Sponsor: Qilu Hospital of Shandong University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module